LVMH Falls, Future Slumps, Dermapharm Drops - podcast episode cover

LVMH Falls, Future Slumps, Dermapharm Drops

Mar 31, 20264 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

On this episode of Stock Movers:
- LVMH, SAP, and Novo Nordisk have slumped by about 30% so far this year, making up about 53% of the total market capitalization shed by constituents of the Stoxx Europe 600 index.
- Future slumps as much as 30%, to the lowest since October 2017, after what JPMorgan describes as a weak first-half trading update, showing impact from pressure on high-margin programmatic advertising and e-commerce revenue, and pay-per-click cost inflation.
- Dermapharm shares fall 4.8% after the company announced full year results. Dermapharm forecast adjusted Ebitda for 2026 of EU331 million to EU341 million.

See omnystudio.com/listener for privacy information.

Transcript

Speaker 1

Bloomberg Audio Studios, podcasts, radio news. The Stock Movers Report, your roundup of companies making moves in the stock market, harnessing the power of Bloomberg Data.

Speaker 2

Let's have a look at some of the stocks on the move today in Europe. I'm Caroline Hipkil I'm joined by reported to you at a BAIO. Good morning. So let's think about stocks in the luxury sector LVMH in particular. Why are we watching this one today?

Speaker 3

Yeah, so this comes amidst a bit of a downturn for some of Europe's biggest companies. It's been happening for quite some time now. There's actually some great reporting about this on the terminal. It's illustrating how just three firms are driving the continents four hundred and twenty billion euro stock route. So LVMH is one of those names. It's down just a little bit today, but on average over the last few months it's been down over eight percent,

so quite a long decline there. And it's a similar story for other stor warts of the Stock six hundred. Names like Novo, Nordisk and SAP slump by about thirty percent so far this year. But the problem is that these companies seem to be overstated in terms of their losses on the index. Their losses really far exceed their combined index waiting of just three percent. So phenomenon to watch there certainly.

Speaker 2

Okay, so that in the luxury sector. Meanwhile, let's turn to Media and Future PLC, which used to publish some of my favorite magazines I suspect as a teenager. What has been happening with this business?

Speaker 3

Well, Future has slumped as much as thirty percent, the lowest since October twenty seventeen, and perhaps slumping as much as the print news sector. Some of those magazines are not as popular as they once work, Caroline, But JP Morgan has described it as a weak first half trading update that gave that's what's moving the stock this morning.

It says that as showing impacts from the pressure on their high margin advertising and e commerce revenue, also some pay per click cost inflation, so that business model not exactly as resilient as it has been and despite some sort of benefits from strategic initiatives and signs of growth, this higher audience pressure is really troubling at this stock. Analyst at JP Morgan writing that their margin for ebert

DA will amiss by about seventeen percent. Miss expectations there, so not great news for future this morning.

Speaker 2

Yeah, absolutely, publishers of Mary Clare Homes and Gardens at least, that's if you're still into what would be quite vintage. Apparently now it's called physical media if you actually buy it and do you hold on to it, it's physical media rather than digital of course. Right, let's think about pharmaceuticals, a job in manufacturer Derma Farm about this sector.

Speaker 3

Yeah, so Derma Farm is down over four percent today. That's after it missed ebit dart expectations for its full year results. Have a bit of a loss there, the market reacting not well. But earlier this month, actually we did see a big jump for Derma Farm, the most since September twenty twenty four, and that was after the manufacturer of these branded pharmaceuticals unveiled plans to buy back

the stock at premium. But it does seem that things have taken a slight turn investors not looking favorably on that myss today for Derma Farm.

Speaker 1

The stock Mover's report from Bloomberg Radio. Check back with us throughout the day for the latest roundup of companies making news on Wall Street, and for the latest market moving headlines. Listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg dot com, and on Applecarplay and Android Auto with the Bloomberg Business App.

Transcript source: Provided by creator in RSS feed: download file
For the best experience, listen in Metacast app for iOS or Android